News
2d
GlobalData on MSNFDA grants 510(k) clearance for Tempus AI’s ejection fraction softwareThe US Food and Drug Administration (FDA) has granted 510(k) clearance for Tempus AI’s ECG-Low (ejection fraction) EF ...
Patients taking Kerendia saw significant reduction in cardiovascular death and hospitalization and urgent visits for heart ...
2don MSN
Researchers at the German Center for Cardiovascular Research (DZHK) have identified a key molecule involved in a form of ...
The new Tempus software analyzes resting, non-ambulatory 12-lead ECG recordings to detect signs associated with having a low ...
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...
The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.
“Weight loss quality is a new concept….The discussion no longer revolves around the lack of adequate efficacy but rather ...
Tempus AI Inc (NASDAQ:TEM) shares are trading higher Wednesday after the company announced that it received 510(k) clearance ...
The era of predictive modeling enhanced with machine learning and artificial intelligence (AI) to aid clinical ...
The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.
Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results